Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $6.7 million.

  • 60 Degrees Pharmaceuticals' Liabilities and Shareholders Equity fell 985.8% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year decrease of 1899.8%. This contributed to the annual value of $5.8 million for FY2024, which is 2600.83% down from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Liabilities and Shareholders Equity stood at $6.7 million, which was down 985.8% from $4.2 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' 5-year Liabilities and Shareholders Equity high stood at $9.2 million for Q3 2023, and its period low was $1.3 million during Q4 2022.
  • For the 4-year period, 60 Degrees Pharmaceuticals' Liabilities and Shareholders Equity averaged around $6.2 million, with its median value being $6.7 million (2025).
  • In the last 5 years, 60 Degrees Pharmaceuticals' Liabilities and Shareholders Equity soared by 50004.12% in 2023 and then plummeted by 4119.57% in 2024.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $1.3 million in 2022, then soared by 500.04% to $7.8 million in 2023, then decreased by 26.01% to $5.8 million in 2024, then rose by 16.15% to $6.7 million in 2025.
  • Its Liabilities and Shareholders Equity was $6.7 million in Q3 2025, compared to $4.2 million in Q2 2025 and $6.0 million in Q1 2025.